We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+7.64%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.56B
AUM Growth
+$19.4M
Cap. Flow
-$249M
Cap. Flow %
-3.79%
Top 10 Hldgs %
37.22%
Holding
183
New
22
Increased
65
Reduced
79
Closed
14

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$38.5M
2
SAGE
Sage Therapeutics
SAGE
+$22M
3
SIBN icon
SI-BONE Inc
SIBN
+$19.1M
4
STE icon
Steris
STE
+$16.6M
5
CLDX icon
Celldex Therapeutics
CLDX
+$15.6M

Top Sells

Rank Stock Value
1
AXNX
Axonics, Inc. Common Stock
AXNX
+$114M
2
ISRG icon
Intuitive Surgical
ISRG
+$56.6M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$51.2M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$28.6M
5
EVH icon
Evolent Health
EVH
+$28.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.12%
2 Industrials 0.77%
3 Technology 0.02%
4 Communication Services 0.02%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DHR icon
76
Danaher
DHR
$144B
$21.5M 0.33%
86,232
+1,922
+2% +$469K
PRVA icon
77
Privia Health
PRVA
$3.39B
$20.7M 0.32%
1,059,171
+7,475
+0.7% +$158K
HCM icon
78
HUTCHMED
HCM
$1.86B
$19.4M 0.3%
1,154,632
+23,521
+2% +$357K
SIBN icon
79
SI-BONE Inc
SIBN
$771M
$18.7M 0.28%
1,139,956
+1,014,756
+811% +$19.1M
VRNA
80
DELISTED
Verona Pharma
VRNA
$18.3M 0.28%
1,139,295
+299,299
+36% +$5.18M
PACB icon
81
Pacific Biosciences
PACB
$447M
$17.2M 0.26%
4,592,251
-2,724,877
-37% -$16M
STE icon
82
Steris
STE
$21.2B
$16.5M 0.25%
+73,434
New +$16.6M
LEGN icon
83
Legend Biotech
LEGN
$4.31B
$16.4M 0.25%
293,270
+91,516
+45% +$5.52M
GBIO
84
DELISTED
Generation Bio
GBIO
$15.7M 0.24%
386,158
+24,450
+7% +$576K
ANNX icon
85
Annexon
ANNX
$950M
$15.6M 0.24%
+2,182,290
New +$11.3M
GPCR icon
86
Structure Therapeutics
GPCR
$3.45B
$15.6M 0.24%
363,926
+351,626
+2,859% +$14.8M
NEO icon
87
NeoGenomics
NEO
$1.9B
$14.9M 0.23%
+946,025
New +$14.6M
ATRC icon
88
AtriCure
ATRC
$1.77B
$13.6M 0.21%
447,376
-370,507
-45% -$12.4M
TXG icon
89
10x Genomics
TXG
$5.55B
$11.6M 0.18%
308,311
+15,138
+5% +$665K
PHR icon
90
Phreesia
PHR
$662M
$10.6M 0.16%
443,341
+21,768
+5% +$541K
OMCL icon
91
Omnicell
OMCL
$2.09B
$6.88M 0.1%
235,372
+11,556
+5% +$350K
REGN icon
92
Regeneron Pharmaceuticals
REGN
$70.9B
$6.81M 0.1%
7,077
-3,632
-34% -$3.45M
AMGN icon
93
Amgen
AMGN
$198B
$6.29M 0.1%
22,139
-12,066
-35% -$3.53M
RMD icon
94
ResMed
RMD
$28.9B
$6.02M 0.09%
30,391
+71
+0.2% +$13K
ILMN icon
95
Illumina
ILMN
$28.2B
$5.99M 0.09%
44,817
-1,436
-3% -$192K
GKOS icon
96
Glaukos
GKOS
$9.21B
$5.27M 0.08%
+55,926
New +$5M
ABBV icon
97
AbbVie
ABBV
$450B
$5.02M 0.08%
27,593
+20,866
+310% +$3.6M
MCK icon
98
McKesson
MCK
$98.5B
$4.83M 0.07%
8,997
+4,144
+85% +$2.1M
RXRX icon
99
Recursion Pharmaceuticals
RXRX
$1.56B
$4.24M 0.06%
425,249
+250,692
+144% +$2.79M
TDOC icon
100
Teladoc Health
TDOC
$1.7B
$4.12M 0.06%
272,798
+13,394
+5% +$243K
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2024 Portfolio in Review

As of Q1 2024, Bellevue Group held 183 positions worth $6.56B, up 0.3% from $6.54B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Bellevue Group withdrew a net $249M in Q1 2024, closing 14 positions and reducing 79 holdings. Its most notable exit was Axonics, Inc. Common Stock, an estimated $114M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials and Technology.

Against the trend, Bellevue Group opened a new position in Steris worth $16.5M.

  • Bellevue Group's largest Q1 2024 buy was Steris: 73,434 shares worth $16.5M.
  • Bellevue Group added most to DexCom in Q1 2024, an estimated $38.5M increase.
  • Bellevue Group's biggest Q1 2024 reduction was Intuitive Surgical, cutting an estimated $56.6M.
  • Bellevue Group fully exited Axonics, Inc. Common Stock in Q1 2024, selling an estimated $114M.
  • Bellevue Group's ten largest holdings make up 37% of its $6.56B portfolio in Q1 2024.
  • Bellevue Group opened 22 new positions and closed 14 in Q1 2024.
  • Bellevue Group's portfolio value rose 0.3% quarter-over-quarter to $6.56B.

Based on Bellevue Group's 13F filing for Q1 2024, filed 15 May 2024.